AIMS/HYPOTHESIS: Protein-mediated trans-membrane and intracellular fatty acid trafficking are becoming increasingly recognised as biochemically and physiologically important concepts. Obesity and insulin resistance are polygenic disorders, heavily influenced by environmental and life-style factors, and are virtually always associated with disturbed fatty acid metabolism in adipose and other tissues. The aim of this study was to investigate mRNA expression levels of fatty-acid-handling proteins in adipose tissue in relation to markers of genetic and acquired obesity and insulin resistance. METHODS: We quantified mRNA expression of subcutaneous adipose tissue fatty-acid-handling proteins (ALBP, KLBP, FATP1, FATP4, CD36, ACS1) in 17 monozygotic twin-pairs with a range of intra-pair differences (Delta) in BMI and detailed measures of obesity and insulin resistance, allowing influences of genetic and non-genetic factors to be distinguished. RESULTS: In acquired obesity FATP4 expression was up-regulated independently of genetic background (DeltaFATP4 versus DeltaBMI; r=0.50, p=0.04; DeltaFATP4 versus Deltabody fat; r=0.59, p=0.01). Similarly, CD36 and FATP1 expression correlated with acquired differences in HDL cholesterol and non-esterified fatty acid concentrations respectively. Moreover, FATP4 and CD36 expression levels correlated with measures of obesity and insulin resistance that are influenced by both genetic and non-genetic factors (FATP4 versus BMI: r=0.53, p=0.0001; FATP4 versus body fat: r=0.51, p=0.002; FATP4 versus homeostasis model assessment [HOMA]: r=0.49, p=0.001; CD36 versus BMI: r=0.50, p=0.02; CD36 versus body fat: r=0.63, p=0.001; CD36 versus HOMA: r=0.34, p=0.06). CONCLUSIONS/ INTERPRETATION: These findings indicate that expression of specific adipose tissue fatty-acid-handling proteins is related to obesity and insulin resistance, and that, in particular, FATP4 plays a role in acquired obesity. Our results suggest that facilitated fatty acid trafficking is a physiologically and pathologically relevant phenomenon in man.
AIMS/HYPOTHESIS: Protein-mediated trans-membrane and intracellular fatty acid trafficking are becoming increasingly recognised as biochemically and physiologically important concepts. Obesity and insulin resistance are polygenic disorders, heavily influenced by environmental and life-style factors, and are virtually always associated with disturbed fatty acid metabolism in adipose and other tissues. The aim of this study was to investigate mRNA expression levels of fatty-acid-handling proteins in adipose tissue in relation to markers of genetic and acquired obesity and insulin resistance. METHODS: We quantified mRNA expression of subcutaneous adipose tissue fatty-acid-handling proteins (ALBP, KLBP, FATP1, FATP4, CD36, ACS1) in 17 monozygotic twin-pairs with a range of intra-pair differences (Delta) in BMI and detailed measures of obesity and insulin resistance, allowing influences of genetic and non-genetic factors to be distinguished. RESULTS: In acquired obesity FATP4 expression was up-regulated independently of genetic background (DeltaFATP4 versus DeltaBMI; r=0.50, p=0.04; DeltaFATP4 versus Deltabody fat; r=0.59, p=0.01). Similarly, CD36 and FATP1 expression correlated with acquired differences in HDL cholesterol and non-esterified fatty acid concentrations respectively. Moreover, FATP4 and CD36 expression levels correlated with measures of obesity and insulin resistance that are influenced by both genetic and non-genetic factors (FATP4 versus BMI: r=0.53, p=0.0001; FATP4 versus body fat: r=0.51, p=0.002; FATP4 versus homeostasis model assessment [HOMA]: r=0.49, p=0.001; CD36 versus BMI: r=0.50, p=0.02; CD36 versus body fat: r=0.63, p=0.001; CD36 versus HOMA: r=0.34, p=0.06). CONCLUSIONS/ INTERPRETATION: These findings indicate that expression of specific adipose tissue fatty-acid-handling proteins is related to obesity and insulin resistance, and that, in particular, FATP4 plays a role in acquired obesity. Our results suggest that facilitated fatty acid trafficking is a physiologically and pathologically relevant phenomenon in man.
Authors: Katja Kannisto; Jussi Sutinen; Elena Korsheninnikova; Rachel M Fisher; Ewa Ehrenborg; Karl Gertow; Antti Virkamäki; Tuulikki Nyman; Hubert Vidal; Anders Hamsten; Hannele Yki-Järvinen Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Kazuhisa Maeda; K Teoman Uysal; Liza Makowski; Cem Z Görgün; Genichi Atsumi; Rex A Parker; Jens Brüning; Ann Vogel Hertzel; David A Bernlohr; Gökhan S Hotamisligil Journal: Diabetes Date: 2003-02 Impact factor: 9.461
Authors: Jose Abraham Viscarra; José Pablo Vázquez-Medina; Ruben Rodriguez; Cory D Champagne; Sean H Adams; Daniel E Crocker; Rudy M Ortiz Journal: J Exp Biol Date: 2012-07-15 Impact factor: 3.312
Authors: James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song Journal: Adv Pharmacol Date: 2013
Authors: Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román Journal: Endocr Metab Immune Disord Drug Targets Date: 2010-06 Impact factor: 2.895
Authors: Carolyn C Allred; Thomas Krennmayr; Christina Koutsari; Lianzhen Zhou; Asem H Ali; Michael D Jensen Journal: J Lipid Res Date: 2010-11-28 Impact factor: 5.922
Authors: Linda Mustelin; Kirsi H Pietiläinen; Aila Rissanen; Anssi R Sovijärvi; Päivi Piirilä; Jussi Naukkarinen; Leena Peltonen; Jaakko Kaprio; Hannele Yki-Järvinen Journal: Am J Physiol Endocrinol Metab Date: 2008-05-06 Impact factor: 4.310